23 results on '"McKinzie, C."'
Search Results
2. 22 Effects of elexacaftor-tezacaftor-ivacaftor on antibiotic use in people with cystic fibrosis
3. 420 Alopecia in children and adults with cystic fibrosis on elexacaftortezacaftor-ivacaftor
4. 549 Pharmacogenomic profiling reveals genetic variants associated with lower vitamin K activity: implications for vitamin K dosing
5. 207 Repeat fecal elastase testing in pediatric patients on cystic fibrosis transmembrane conductance regulator modulator therapy
6. 256 Tobramycin pharmacokinetic differences in patients after initiation of highly effective modulator therapy
7. 208 Fat-soluble vitamin level trends after elexacaftor/tezacaftor/ivacaftor therapy
8. 219 Changes in the relationship between body mass index and forced expiratory volume in 1 second after initiation of elexacaftor/tezacaftor/ivacaftor therapy
9. 49 Medication adherence and lung function changes with elexacaftor/tezacaftor/ivacaftor treatment
10. 444 Elexacaftor/tezacaftor/ivacaftor treatment reduces airway inflammation in cystic fibrosis
11. 506 Pharmacogenomic variation influences elexacaftor/tezacaftor/ivacaftor concentrations in people with CF.
12. 499 Mental health diagnosis and medication changes after initiation of elexacaftor/tezacaftor/ivacaftor.
13. SKI AREA DEVELOPMENT AFTER THE NATIONAL FOREST SKI AREA PERMIT ACT OF 1986: STILL AN UPHILL BATTLE
14. 742 Improving screening for bone health at a pediatric cystic fibrosis program.
15. 549 Screening for behavioral changes after elexacaftor/tezacaftor/ivacaftor initiation in children aged 2 to 5.
16. 498 Exploring clinical practices regarding highly effective modulator therapy in pregnancy and postnatal care.
17. 497 Management strategies for hepatotoxicity associated with elexacaftor/tezacaftor/ivacaftor: results of a provider survey.
18. 331 CF airway inflammation enhances elexacaftor/tezacaftor/ivacaftormediated rescue of N1303K CFTR.
19. 96 Impact of elexacaftor/tezacaftor/ivacaftor on antibacterial resistance in people with cystic fibrosis.
20. 368 Genetic variation predicts non-pulmonary outcomes of elexacaftor/tezacaftor/ivacaftor treatment in people with cystic fibrosis.
21. Development of an electronic trigger tool at a children's hospital within an academic medical center.
22. Measured fetal and neonatal exposure to Lumacaftor and Ivacaftor during pregnancy and while breastfeeding.
23. Exploring the effect of stress on mood, self-esteem, and daily habits with psychology graduate students.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.